Immunotherapy for advanced renal cell carcinoma;Immuntherapie des fortgeschrittenen nierenzellkarzinoms

Urologe - Ausgabe A

Volumn 43, Issue 1, 2004, Pages 85-93

  Aulitzky, W E ^a   Kaufmann, M ^a  

^a ROBERT BOSCH HOSPITAL   (Germany)

Author keywords

Advanced disease; IFN ; Immunotherapy; Renal cell carcinoma; Survival

Indexed keywords

7 HYDROXYSTAUROSPORINE; ALPHA INTERFERON; ARSENIC TRIOXIDE; BEVACIZUMAB; BORTEZOMIB; BRYOSTATIN 1; CANCER VACCINE; CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; GEFITINIB; GEMCITABINE; GESTAGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMATINIB; INTERLEUKIN 2; INTERLEUKIN 4; ISOTRETINOIN; MAJOR HISTOCOMPATIBILITY ANTIGEN; MEDROXYPROGESTERONE ACETATE; RAMPIRNASE; RECOMBINANT INTERLEUKIN 2; RIBONUCLEASE; TEMSIROLIMUS; THALIDOMIDE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VATALANIB; VINBLASTINE; ANTINEOPLASTIC AGENT; IMMUNOSUPPRESSIVE AGENT;

ADVANCED CANCER; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; KIDNEY CARCINOMA; OUTCOMES RESEARCH; REVIEW; CLINICAL PRACTICE; IMMUNOLOGY; IMMUNOTHERAPY; KIDNEY TUMOR; METHODOLOGY; PRACTICE GUIDELINE; PROGNOSIS; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; PROGNOSIS; TREATMENT OUTCOME;

EID: 3042701583     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00120-003-0502-5     Document Type: Review

References (15)

1. Anonymous (1999) Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet 353: 14-17
2. Atzpodien J, Kirchner H, Illiger HJ et al. (2001) IL-2 in combination with IFN-alpha and 5-FU vs. tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br J Cancer 85(8): 1130-1136
3. Aulitzky WE, Beck J, Huber C (2003) Nierenzellkarzinom. In: Hiddemann W, Huber C, Bartram CR (Hrsg) Die Onkologie, Springer, Berlin Heidelberg New York Tokio
4. Bukowski RM (1997) Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer 80: 1198-1220
5. Childs R, Chernoff A, Contentin N et al. (2000) Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneicperipheral-blood stem-cell transplantation. N Engl J Med 343: 750-758
6. Coppin C, Porzsolt F, Kumpf J, Coldman A, Wilt T (2000) Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev (3): CD001425. (Review)
7. Gleave ME, Elhilali M, Fradet Y et al. (1998) Interferon-γ-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group. N Engl J Med. 338 (18): 1265-1271
8. Flanigan RC, Salmon SE, Blumenstein BA et al. (2001) Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345 (23): 1655-1659
9. Hoelzel D, Klamert A, Schmidt C (1996) Nierenkarzinom. In: Krebs: Häufigkeiten, Befunde, Behandlungsergebnisse. Zuckschwerdt, München, S 399-409
10. Michael A, Pandha H (2003) Renal-cell carcinoma: tumour markers, T-cell epitopes and potential for new therapies. Lancet Oncol 4: 215-223
11. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R; European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group (2001) Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358 (9286): 966-970
12. Pardoll D (2003) Does the immune system see tumors as foreign or self? Ann Rev Immunol 21: 807-839
13. Pyrhönen S, Salminen E, Ruutu M et al. (1999) Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Onc 17: 2859
14. Strair RK, Schaar D, Medina D et al. (2003) Antineoplastic effects of partially HLA-matched irradiated blood mononuclearcells in patients with renal cell carcinoma. J Clin Oncol. 21 (20): 3785-3791
15. Yagoda A, Abi-Rached B, Petrylak D (1995) Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin Oncol 22: 42-60